Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Vaccine in Older Korean Adults
NCT06593587Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Oct 2024; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06593587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593587.